CDRH Inspection CPG Omits "Fatal Flaw" And Minor Nonconformities Clauses
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed policy of halting routine inspections when a serious nonconformance is identified has been removed from its final compliance program guide for medical device audits, released Feb. 8.
You may also be interested in...
Budget Crunch Forces CDRH To Abbreviate Baseline Device GMP Inspections
CDRH plans to dramatically increase its inspections of domestic medical device facilities performed this year by reviewing only two of the four major QSIT subsystems in each "baseline" audit.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”